Related references
Note: Only part of the references are listed.Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase
Tingting Sun et al.
CELL (2011)
p53 Status Identifies Two Subgroups of Triple-negative Breast Cancers with Distinct Biological Features
Elia Biganzoli et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Unmeasured Costs of a Child's Death: Perceived Financial Burden, Work Disruptions, and Economic Coping Strategies Used by American and Australian Families Who Lost Children to Cancer
Veronica Dussel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
Daniel J. Toft et al.
MOLECULAR ENDOCRINOLOGY (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
Joyce O'Shaughnessy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Treatment of HER2-overexpressing breast cancer
J. Baselga
ANNALS OF ONCOLOGY (2010)
Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up
Lisa Ryden et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Triple-Negative Breast Cancer Role of Specific Chemotherapy Agents
Steven J. Isakoff
CANCER JOURNAL (2010)
LYN Is a Mediator of Epithelial-Mesenchymal Transition and a Target of Dasatinib in Breast Cancer
Yoon-La Choi et al.
CANCER RESEARCH (2010)
The met receptor tyrosine kinase and basal breast cancer
Marisa G. Ponzo et al.
CELL CYCLE (2010)
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Monika Graeser et al.
CLINICAL CANCER RESEARCH (2010)
Beyond triple-negative breast cancer: the need to define new subtypes
Anastasia Constantinidou et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality
Elena Lopez-Knowles et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
David W. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Li Ding et al.
NATURE (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins
Hideki Asakawa et al.
BREAST CANCER RESEARCH (2010)
Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer
G. Frasci et al.
ANNALS OF ONCOLOGY (2009)
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
B. K. Linderholm et al.
ANNALS OF ONCOLOGY (2009)
Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis
Britta Weigelt et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
T. Byrski et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype
Monzur Rahman et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Invasive ductal carcinoma of the breast with the triple-negative phenotype: prognostic implications of EGFR immunoreactivity
Giuseppe Viale et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
Olga K. Mirzoeva et al.
CANCER RESEARCH (2009)
Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics
Bryan T. Hennessy et al.
CANCER RESEARCH (2009)
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Emad A. Rakha et al.
CLINICAL CANCER RESEARCH (2009)
Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
G. Solinas et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components
Caterina Marchio et al.
JOURNAL OF PATHOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes
Olafur Andri Stefansson et al.
BREAST CANCER RESEARCH (2009)
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
F. -C. Bidard et al.
ANNALS OF ONCOLOGY (2008)
Platinum-based chemotherapy in triple-negative breast cancer
B. Sirohi et al.
ANNALS OF ONCOLOGY (2008)
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
Bhumsuk Keam et al.
BMC CANCER (2008)
Triple-Negative Breast Cancer and Obesity in a Rural Appalachian Population
Linda Vona-Davis et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells
Kehy L. Mueller et al.
CANCER RESEARCH (2008)
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype
David Sarrió et al.
CANCER RESEARCH (2008)
Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
Alfonso Sanchez-Munoz et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2008)
RiBBON 1 and RiBBON 2: Phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer
Joyce A. O'Shaughnessy et al.
CLINICAL BREAST CANCER (2008)
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
Christine Desmedt et al.
CLINICAL CANCER RESEARCH (2008)
Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype
Maggie C. U. Cheang et al.
CLINICAL CANCER RESEARCH (2008)
Triple negative breast cancer: current understanding of biology and treatment options
Soonmo Peter Kang et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2008)
Expression of BRCAI protein in breast cancer and its prognostic significance
Emad A. Rakha et al.
HUMAN PATHOLOGY (2008)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
The basal-like breast carcinoma phenotype is regulated by SLUG gene expression
G. Storci et al.
JOURNAL OF PATHOLOGY (2008)
Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes
Anthony Goncalves et al.
MOLECULAR & CELLULAR PROTEOMICS (2008)
αB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer
Olga Ivanov et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer
Mitsunori Sasa et al.
JOURNAL OF SURGICAL ONCOLOGY (2008)
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
David S. P. Tan et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Triple negative tumours: a critical review
J. S. Reis-Filho et al.
HISTOPATHOLOGY (2008)
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells
Berengere Marty et al.
BREAST CANCER RESEARCH (2008)
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas
Jason I. Herschkowitz et al.
BREAST CANCER RESEARCH (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Increased phosphorylation of Akt in triple-negative breast cancers
Shinobu Umemura et al.
CANCER SCIENCE (2007)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative'' breast cancer cell lines growing in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
EGFR associated expression profiles vary with breast tumor subtype
Katherine A. Hoadley et al.
BMC GENOMICS (2007)
Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype
Stephane Garcia et al.
HUMAN PATHOLOGY (2007)
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers
Chee-Onn Leong et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy
Raihanatou Diallo-Danebrock et al.
CLINICAL CANCER RESEARCH (2007)
Essential role for nuclear PTEN in maintaining chromosomal integrity
Wen Hong Shen et al.
CELL (2007)
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer
Andrew E. Teschendorff et al.
GENOME BIOLOGY (2007)
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
Jason I. Herschkowitz et al.
GENOME BIOLOGY (2007)
Prognostic markers in triple-negative breast cancer
Emad A. Rakha et al.
CANCER (2007)
Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity
Anne Vincent-Salomon et al.
BREAST CANCER RESEARCH (2007)
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
Bas Kreike et al.
BREAST CANCER RESEARCH (2007)
Basal-like breast cancer and the BRCA1 phenotype
N. C. Turner et al.
ONCOGENE (2006)
Targeting tumor-associated macrophages as a novel strategy against breast cancer
Yunping Luo et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Basal-like breast carcinomas: clinical outcome and response to chemotherapy
S. Banerjee et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast
L. G. Fulford et al.
HISTOPATHOLOGY (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Biphasic metaplastic sarcomatoid carcinoma of the breast
BT Hennessy et al.
ANNALS OF ONCOLOGY (2006)
Molecular alterations in columnar cell lesions of the breast
DJ Dabbs et al.
MODERN PATHOLOGY (2006)
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
CA Livasy et al.
MODERN PATHOLOGY (2006)
alpha B-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer
JV Moyano et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation
T Shien et al.
JOURNAL OF CLINICAL PATHOLOGY (2005)
High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
DM Abd El-Rehim et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers
J Palacios et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Expression profiling of purified normal human luminal and myoepithelial breast cells: Identification of novel prognostic markers for breast cancer
C Jones et al.
CANCER RESEARCH (2004)
The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer
WD Foulkes et al.
CANCER RESEARCH (2004)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
The role of BRCA1 in the cellular response to chemotherapy
RD Kennedy et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer
WD Foulkes et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Breast cell invasive potential relates to the myoepithelial phenotype
LA Gordon et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
BRCA I expression modulates chemosensitivity of BRCA I-defective HCC1937 human breast cancer cells
P Tassone et al.
BRITISH JOURNAL OF CANCER (2003)
IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells
A Freund et al.
ONCOGENE (2003)
Host microenvironment in breast cancer development - Epithelial-mesenchymal transition in breast cancer development
A Vincent-Salomon et al.
BREAST CANCER RESEARCH (2003)
Cytogenetic alterations and cytokeratin expression patterns in breast cancer: Integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis
E Korsching et al.
LABORATORY INVESTIGATION (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach
C Beger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases
H Tsuda et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2000)
Share Paper
